Emerging patents versus brain eating amoebae, Naegleria fowleri

Ruqaiyyah Siddiqui, David Lloyd, Naveed Ahmed Khan*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

Abstract

Primary Amoebic Meningoencephalitis (PAM) is a severe and often fatal infection caused by the free-living amoebae Naegleria fowleri. This condition typically results from exposure to contaminated warm freshwater/inadequately treated recreational water/or ablution/nasal irrigation with contaminated water. The management of PAM is hindered by the absence of effective treatment coupled with challenges in early diagnosis. This review explores emerging patents that could be utilized for the treatment, diagnosis of PAM, as well as water treatment. Recent patents from the past five years, along with research and innovations are reviewed and categorized into therapeutic agents, water treatment technologies, and diagnostic methods. It is hoped that collaboration and awareness between pharmaceutical companies, water industries, and academic institutions is essential for advancing effective strategies against this severe central nervous system pathogen.

Original languageEnglish
JournalPharmaceutical Patent Analyst
Early online date3 Feb 2025
DOIs
Publication statusE-pub ahead of print - 3 Feb 2025

Keywords

  • brain eating amoebae
  • central nervous system infections
  • Naegleria fowleri
  • patents
  • primary amebic meningoencephalitis

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Drug Discovery

Fingerprint

Dive into the research topics of 'Emerging patents versus brain eating amoebae, Naegleria fowleri'. Together they form a unique fingerprint.

Cite this